AMG-337 is under clinical development by Amgen and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AMG-337’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AMG-337 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AMG-337 is under development for the treatment of solid tumors. It is a small molecule administered orally in the form of a capsule. It acts by targeting c-Met. It was also under development for the treatment of hepatocellular carcinoma, clear cell sarcoma, advanced or metastatic gastric cancer and gastroesophageal junction, esophageal adenocarcinoma.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.
Quick View AMG-337 LOA Data
|Highest Development Stage|